|
|
社会责任
Responsibility
Chengdu Huaxi Hai (National Chengdu Safety Evaluation Center) laboratory animal supply center
Since its establishment in 2002, the company has been working with Chengdu Huaxi Hai Qi Biotechnology Co., Ltd. Over the past ten years, our company has given priority to 500 high-quality monkeys in the West China Sea every year. It has effectively protected the development of Huaxi Hai Qi's various experimental projects, and has made positive contributions to human drug research and development.
"The green mountain green water, is the Jinshan Yinshan". Respond to the call and pay attention to environmental protection
In green house, we strive to protect the environment and reduce the pressure of natural resources. In 2013, we invested huge sums of money to introduce a sewage treatment system to meet the national level emission standards. We have set up environmental, healthy and safe operating procedures for the workplace, save electricity, save water, and use air heating technology to warm our cynomolgus population in winter.
Our company has been awarded the national science and technology progress award of Sichuan in 2016.
Preclinical evaluation of drugs is important to people's safety and effectiveness. The project has lasted for more than ten years. It has established international standards for the evaluation of pre clinical research and evaluation of drugs. It has gained many authoritative international certification and fully realized international mutual recognition. It has become an important part of the technology support system for new drug research and development in China.
The golden age of Chinese medicine industry
In March 13th, Zhao Bing, an analyst at the Chinese medicine industry of UBS, said in the media conference that the future medical insurance payment model would be an important factor in the drug pricing system. At present, the growth of medical insurance expenditure in China is higher than the growth rate of financing, which will make the medical insurance charge become the core of medical reform policy for a long time in the future. The price of medicine will present a long-term downward trend, and the growth of the medical industry will slow to about 10% in the next three years.